武汉艾必赛生物有限公司推荐Anti-Human Claudin-18.2 Reference Antibody (Infutatug, RUO) ,精品抗体

链接：https://www.abinscience.cn/product/34/56290.html

名称：Anti-Human Claudin-18.2 Reference Antibody (Infutatug, RUO)

货号：HX126076

种属反应性：Human

应用：ELISA, FACS, Functional assay

宿主：Human

同种型：IgG1, kappa

克隆类型：Monoclonal

靶标：CLDN18, Claudin-18

内毒素水平：< 10 EU/mg

纯度：>95% as determined by SDS-PAGE.

纯化方式：Protein A/G purified from cell culture supernatant.

Accession号：P56856

状态：Liquid

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

产品介绍：Anti-Human CLDN18.2 Reference Antibody (Infutatug, RUO)｜HX126076 是艾必赛生物（abinScience）推出的科研级 CLDN18.2 参照/参考抗体，靶向人 Claudin-18.2（CLDN18.2，UniProt P56856），可作为 CLDN18.2 抗体药物、双抗/ADC/CAR-T 研发中的阳性参照、PK/ADA 方法开发及 FACS/ELISA/功能性 assay 质控工具。产品按 abinScience CLDN18/CLDN18.2 参考抗体系列常规工艺制备：哺乳动物细胞表达、糖基化更接近天然构象，经 Protein A/G 纯化，SDS-PAGE 纯度 >95%；液体形式保存于 0.01M PBS, pH 7.4（具体缓冲以 56290 产品页/批次 COA 为准），常用 2–8°C，长期建议 -20°C 或 -80°C、手动除霜冰箱保存、避免反复冻融，自收货起 ≤12 个月。（RUO，仅限科研/非临床用途）

CLDN18.2 是紧密连接蛋白 Claudin-18 的胃型剪接异构体，正常主要局限于分化胃黏膜上皮，在胃癌、胃食管结合部腺癌、胰腺癌等实体瘤中可异常高表达并暴露于细胞表面，因此成为继 HER2 之后消化道肿瘤的重要靶点。 靶向路径覆盖单克隆抗体（如佐妥昔单抗 Zolbetuximab，已用于 CLDN18.2 阳性、HER2 阴性晚期胃癌一线）、双特异性抗体、ADC、CAR-T 等； HX126076 可作为这些管线做受体结合、流式染色、功能中和/竞争、免疫原性对照的科研级参考抗体

产品购买联系方式：027-87433958/17302791434

邮箱：info@abinscience.com

参考文献：

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. PMID: 37524953

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. PMID: 37068504

CLDN18.2-Targeted Therapy in Gastrointestinal Cancers. PMID: 41374966

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. PMID: 37582713

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. PMID: 40670773

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. PMID: 37364935

CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma. PMID: 40206086

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. PMID: 33610734

CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. PMID: 37507075

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. PMID: 35811317

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. PMID: 40460847

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. PMID: 36969060

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. PMID: 38830992

Gastric Cancer: A Review. PMID: 41499132

CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives. PMID: 41517852

Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review. PMID: 40647419

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. PMID: 41513443

CD64(+) fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8(+) T cells. PMID: 39187291

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. PMID: 41033281

Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. PMID: 38200591

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. PMID: 35534566

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors. PMID: 37842662

The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis. PMID: 39461890

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers. PMID: 39321207

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID: 41840238

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. PMID: 35642043

Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. PMID: 38188462

CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing. PMID: 42326542

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. PMID: 40586719

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. PMID: 19047087

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. PMID: 36610262

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8(+) T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade. PMID: 41667243

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。